Literature DB >> 1281953

Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.

D W Dickson1, H Ksiezak-Reding, W K Liu, P Davies, A Crowe, S H Yen.   

Abstract

Antibodies to multiple epitopes spanning the length of the tau molecule were used to study Alzheimer neurofibrillary tangles (NFT) using immunocytochemical methods and several different methods of fixation and tissue processing, including staining of vibratome sections, hydrated autoclaving of paraffin sections and immunofluorescence of NFT isolated from fresh brain tissue. Smears and sections were pretreated with trypsin and/or phosphatase to further characterize antibody binding. In tissue fixed briefly in periodate-lysine-paraformaldehyde, tau immunoreactivity was detected in astrocytes, but only a few tau epitopes were detected in NFT with this fixation method. In contrast, all tau epitopes were detected in NFT in tissue fixed in formaldehyde for prolonged periods of time. In the hippocampus, the number of NFT detected in the dentate fascia was in proportion to the duration of dementia, as we previously noted. Dentate fascia NFT were intracellular (i-NFT) and were reactive with antibodies recognizing epitopes in both the carboxy- and amino-terminal regions of tau, but not the microtubule-binding domain of tau, suggesting that microtubule-binding domain epitopes are hidden in i-NFT. In contrast, NFT in the subiculum and layer II of the parahippocampal cortex were mostly extracellular (e-NFT), especially in severe cases of long duration. e-NFT were immunoreactive with antibodies to the microtubule-binding domain, but only weakly reactive with antibodies to carboxy- or amino-terminal epitopes, suggesting that e-NFT may contain fragments of tau. In both isolated NFT and NFT in sections, amino-terminal epitopes, including the Alz-50 epitope, were sensitive to trypsin proteolysis, which suggests that the lack of staining of e-NFT by antibodies to the amino-terminal regions of tau is due to proteolysis. Antibodies reactive with amino-terminal epitopes also stained fewer NFT following hydrated autoclaving, while those reacting with the carboxy half of tau stained more NFT after hydrated autoclaving. Thus, although carboxy-terminal regions are not detected in e-NFT, they are probably masked, rather than proteolytically cleaved, since they can be revealed by hydrated autoclaving. Finally, phosphatase treatment of isolated NFT revealed enhanced immunostaining not only with Tau-1, as in previous studies demonstrating abnormal phosphorylation of tau proteins in NFT, but also with an antibody to exon 2, which reveals yet another phosphorylation site in tau of NFT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281953     DOI: 10.1007/BF00227736

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  50 in total

1.  Straight and paired helical filaments in Alzheimer disease have a common structural unit.

Authors:  R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

2.  Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

Authors:  C R Harrington; E B Mukaetova-Ladinska; R Hills; P C Edwards; E Montejo de Garcini; M Novak; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

4.  Alz-50 recognizes a phosphorylated epitope of tau protein.

Authors:  K Uéda; E Masliah; T Saitoh; S L Bakalis; H Scoble; K S Kosik
Journal:  J Neurosci       Date:  1990-10       Impact factor: 6.167

5.  Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method.

Authors:  K Kure; W D Lyman; K M Weidenheim; D W Dickson
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

6.  Reappraisal of the fine structure of Alzheimer's neurofibrillary tangles.

Authors:  S Yagishita; Y Itoh; W Nan; N Amano
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

7.  Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides.

Authors:  S H Yen; A Crowe; D W Dickson
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

8.  Alz 50, a monoclonal antibody to Alzheimer's disease antigen, cross-reacts with tau proteins from bovine and normal human brain.

Authors:  H Ksiezak-Reding; P Davies; S H Yen
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

9.  Heterogeneity of tau proteins in Alzheimer's disease. Evidence for increased expression of an isoform and preferential distribution of a phosphorylated isoform in neurites.

Authors:  W K Liu; D W Dickson; S H Yen
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

10.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

View more
  27 in total

1.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors:  Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

2.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Phosphorylated tau immunoreactivity of granulovacuolar bodies (GVB) of Alzheimer's disease: localization of two amino terminal tau epitopes in GVB.

Authors:  D W Dickson; W K Liu; Y Kress; J Ku; O DeJesus; S H Yen
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

Review 5.  Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo.

Authors:  D T Weldon; S D Rogers; J R Ghilardi; M P Finke; J P Cleary; E O'Hare; W P Esler; J E Maggio; P W Mantyh
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

6.  Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat.

Authors:  Ronald L Klein; Robert D Dayton; Wen-Lang Lin; Dennis W Dickson
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

7.  Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy.

Authors:  M B Feany; H Ksiezak-Reding; W K Liu; I Vincent; S H Yen; D W Dickson
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Widespread cytoskeletal pathology characterizes corticobasal degeneration.

Authors:  M B Feany; D W Dickson
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

9.  Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles.

Authors:  D S Horoupian; P L Chu
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration.

Authors:  H Ksiezak-Reding; K Morgan; L A Mattiace; P Davies; W K Liu; S H Yen; K Weidenheim; D W Dickson
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.